WO2022045996A1 - Procédé de production contenant des cellules souches mésenchymateuses, du plasma riche en plaquettes et des chondrocytes encapsulés avec de l'acide hyaluronique-collagène pour le traitement de l'ostéoarthrite - Google Patents

Procédé de production contenant des cellules souches mésenchymateuses, du plasma riche en plaquettes et des chondrocytes encapsulés avec de l'acide hyaluronique-collagène pour le traitement de l'ostéoarthrite Download PDF

Info

Publication number
WO2022045996A1
WO2022045996A1 PCT/TR2020/050782 TR2020050782W WO2022045996A1 WO 2022045996 A1 WO2022045996 A1 WO 2022045996A1 TR 2020050782 W TR2020050782 W TR 2020050782W WO 2022045996 A1 WO2022045996 A1 WO 2022045996A1
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
treatment
joint
hyaluronic acid
osteoarthritis
Prior art date
Application number
PCT/TR2020/050782
Other languages
English (en)
Inventor
Saadet ATSÜ
Original Assignee
Atsue Saadet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atsue Saadet filed Critical Atsue Saadet
Publication of WO2022045996A1 publication Critical patent/WO2022045996A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Definitions

  • the invention is related to a product and production method that can be used for the treatment of joint osteoarthritis in the medical and pharmaceutical industries, and that contain joint chondroprotective-regenerative agents such as mesenchymal stem cell, platelet-rich plasma, chondrocyte and their combinations encapsulated with hyaluronic acid- collagen.
  • joint chondroprotective-regenerative agents such as mesenchymal stem cell, platelet-rich plasma, chondrocyte and their combinations encapsulated with hyaluronic acid- collagen.
  • Osteoarthritis is a joint disease that mainly affects the joint cartilage. Degeneration in the joint cartilage causes pain and limitation of joint movements over time. Osteoarthritis, which is a degenerative joint disease, is an inflammatory condition characterized by progressive erosion, fibrillation of the articular cartilage, and degeneration of the subchondral bone. The treatment of cartilage structures is quite difficult because of the low healing potential of the cartilage tissues and lack of vascularization. For this reason, cellbased therapies have recently been receiving more attention and gaining popularity in regenerative medicine as well as in dentistry.
  • the invention is related to a product and production method that contain chondroprotective-regenerative agents for joint structure such as mesenchymal stem cell, platelet-rich plasma, chondrocyte and their combinations encapsulated with hyaluronic acid- collagen, and that enables joint chondroprotective-regenerative agents such as mesenchymal stem cell, platelet-rich plasma, chondrocyte to be used in regenerative treatment to survive in the medium by encapsulation, and the release of bioactive molecules to the medium for a longer period of time.
  • chondroprotective-regenerative agents for joint structure such as mesenchymal stem cell, platelet-rich plasma, chondrocyte and their combinations encapsulated with hyaluronic acid- collagen
  • An aim of the invention is to use a mixture of hyaluronic acid (HA) and collagen as encapsulation material due to the cartilage and joint protective properties of this mixture.
  • HA hyaluronic acid
  • collagen one of the main components of the extracellular matrix
  • the main functions of hyaluronic acid are to slow down the effects of inflammation on wound healing and support cell proliferation and reepithelization. It has an important role as a lubricant in the joint structure, it protects the cartilage, helps in feeding the cartilage and avascular parts of the disc.
  • Encapsulation materials are prepared by combining hyaluronic acid, which is normally used in joint treatment by increasing viscosity in the joint, with collagen and their beneficial effects in the joint are utilized.
  • Another aim of the invention is to enable the use of platelet-rich plasma (PRP) and its encapsulation with hyaluronic acid (HA) and collagen mixture in order to have a regenerative effect on cartilage degeneration.
  • PRP platelet-rich plasma
  • HA hyaluronic acid
  • collagen mixture in order to have a regenerative effect on cartilage degeneration.
  • PRP contributes to cell proliferation, chondrocyte differentiation and tissue remodeling. It has potential healing effect.
  • Another aim of the invention is to enable the use of chondrocyte and its encapsulation with hyaluronic acid-collagen mixture to create a chondrogenic effect on cartilage degeneration. This will increase chondrogenic activity and damaged tissue regeneration.
  • Another aim of the invention is to provide a product that can be used as a regenerative and chondroprotective treatment method for the treatment of osteoarthritis by encapsulating mesenchymal stem cells, PRP and chondrocytes with hyaluronic acid-collagen encapsulation material, and in this way utilize the synergistic effects of these substances, whose individual regenerative and chondroprotective properties are known.
  • Another aim of the invention is to provide a product that takes less time and can be a definitive solution as an alternative to the known treatment methods for the treatment of osteoarthritis by the injection of stem cells and PRP encapsulated with HA-collagen that is chondroprotective in TMJ (temporomandibular joint) degenerative disorders and all joint osteoarthritises both individually and in combinations.
  • Another aim of the invention is to provide an alternative regenerative treatment method for the treatment of osteoarthritis with primary chondrocytes encapsulated with HA-collagen alone or together with PRP without using stem cells.
  • the present invention will become a preferred product in the industry. In this way, both commercial success will be achieved and an effective treatment method for osteoarthritis will be provided to the medical industry.
  • the invention enables the bioactive molecules originating from stem cells, chondrocytes and PRP hold in the encapsulation material to be released into the joint space for a longer period of time and have a longer lasting effect. Since the encapsulation material will allow the substances in the joint fluid to reach the stem cells, the stem cells will stay in the medium for a longer period of time. The encapsulation material also improves the viscosity of the joint and provides an extra effect.
  • the invention is a product and production method that contains chondroprotective- regenerative agents encapsulated with hyaluronic acid-collagen individually or in combination for the treatment of joint osteoarthritis.
  • the invention may use mesenchymal stem cell, platelet-rich plasma and chondrocyte, and their combinations as chondroprotective-regenerative agent for the joint structure.
  • TMJ osteoarthritis model of the mesenchymal stem cells and PRP encapsulated with chondroprotective hyaluronic acid-collagen mixture and their synergistic effects in in vitro and in vivo rabbit samples have been created with a special technique in this invention, and a regenerative treatment method has been developed with the final product.
  • a TMJ osteoarthritis model has been developed with this technique, it can be applied as a regenerative and chondroprotective treatment method in all joint structures in the body.
  • PRP platelet-rich plasma
  • stem cell encapsulation is performed to protect the cells and ensure that the cells stay together and show a synergistic effect, stay in the medium for a longer period of time and the cell-derived bioactive molecules are released to the medium for a longer period of time.
  • the encapsulation material used in the invention should be biocompatible. It should ensure that nutrients reach the cells and stay in the medium for the desired time.
  • the encapsulation process can be performed using only PRP instead of stem cells.
  • the encapsulation process can also be performed by using chondrocytes instead of stem cells.
  • the invention presents an alternative regenerative treatment method for osteoarthritis by using primary chondrocytes alone or together with PRP in HA- collagen encapsulation without using stem cells.
  • HA/Collagen encapsulation material has been prepared to protect the cells and ensure that the cells stay together and show a synergistic effect, stay in the medium for a longer period of time and the cell-derived bioactive molecules are released to the medium for a longer period of time.
  • HA/Collagen encapsulation material is biocompatible, allows nutrients to reach to the cells, to stay in the medium for the desired time, and it is non-toxic and in addition has cartilage and joint protective properties. For these reasons it is among the most preferred materials.
  • Collagen Type II Nutragen
  • hyaluronic acid and 4 arm Polyethylene Glycol Succinimidyl Glutaramide (4sPEG) (Jenkem Technology) as crosslinking agent have been used.
  • HA and 4sPEG have been exposed to UV light for 30 minutes.
  • 2 ml (5 mg/ml) of HA prepared in 15 ml vial has been added in 2 ml of collagen by pipetting with a micropipette.
  • it has been added in 500 ml of 4sPEG mixture with a micropipette and thoroughly mixed. After being cultured in an oven for 1 hour at 37°C 5% CO 2 it became ready.
  • Capsules that disintegrate every other day are proportioned to those that do not disintegrate by using a microscope.
  • the encapsulation of the cell is performed with the help of a micropipette or peristaltic pump, and the final product is obtained.
  • the fat tissue samples obtained from rabbit are used in the primary culture stage of the stem cells from the fat tissue.
  • the fat tissue samples are broken into small pieces for enzymatic disintegration phase and kept for 1 hour in collagenase (99.8% DMEM, 2% Collagenase) enzyme.
  • collagenase 99.8% DMEM, 2% Collagenase
  • the sample is centrifuged at 12000 rpm for 2 minutes, and the cells taken from the bottom of the centrifuge tube are transferred to 12.5 cm 2 of cell culture flasks with 5 ml of DMEM (88% DMEM, 10% Fetal Calf Serum, 2% L-Glutamine, Streptomycin-Ampicillin) and taken into the oven (at 100% humidity, 37°C, 5% CO 2 ).
  • the proliferating cells are expected to have aggregated fusiform morphology under light microscope.
  • the stem cells are characterized according to the presence of CD12, CD90, CD105 cell surface receptors by applying flow cytometry at each passage until the determined passages.
  • stem cell negative markers CD34 and CD45 are used. If necessary, other markers such as CD19, CD11-B can be used.
  • the cartilage tissues taken from rabbit under sterile conditions are divided into small pieces with the help of sterile scalpels and planted in 25 cm 2 flasks. They are incubated in oven for 1 week at 37°C 5% CO 2 by adding a medium containing 89% DMEM (Dulbecco's Modified Eagles Medium), 10% FBS (Fetal Bovine Serum), 1% Penicillin-Streptomycin. After enough cells are isolated, the media of the cells attached to the flasks are discarded and it is treated with 0.5 ml of trypsin EDTA and incubated for 4 minutes. At the end of the incubation, the cells are checked and removed by using mechanical force.
  • DMEM Dynamic Eagle's Modified Eagles Medium
  • FBS Fetal Bovine Serum
  • Penicillin-Streptomycin Penicillin-Streptomycin
  • a medium containing 1 ml of serum is added to the cells transferred to the sterile falcon tube to inhibit trypsin activation, and then it is centrifuged at 2500 rpm for 2 minutes, and passaged into new flasks by adding 3 ml of medium for each flask on the obtained pellet.
  • Primary chondrocytes in the cell culture are confirmed by flow cytometry with markers CD44, CD49c and CD151 against differentiation from the culture medium or contamination by other cells.
  • the application is made in the form of injection to the joint area.
  • Encapsulated mesenchymal stem cells are injected into the joint area at the required value.
  • injection is made by encapsulating the encapsulated PRP or PRP and mesenchymal stem cells together.
  • chondrocyte application chondrocyte encapsulated with HA-collagen is injected either alone or together with PRP.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un produit chondrogénique, régénérateur-chondroprotecteur et un procédé de production qui peut être utilisé pour le traitement de l'ostéoarthrite articulaire dans les industries médicales et pharmaceutiques, et qui contiennent une cellule souche mésenchymateuse, du plasma riche en plaquettes et un chondrocyte, ou leurs combinaisons encapsulés avec de l'acide hyaluronique et du collagène, et qui permettent la survie plus longue des cellules souches mésenchymateuses, du plasma riche en plaquettes et des chondrocytes dans le milieu sur une période de temps plus longue par encapsulation et la libération des molécules bioactives au niveau du milieu sur une période de temps plus longue.
PCT/TR2020/050782 2020-08-26 2020-08-28 Procédé de production contenant des cellules souches mésenchymateuses, du plasma riche en plaquettes et des chondrocytes encapsulés avec de l'acide hyaluronique-collagène pour le traitement de l'ostéoarthrite WO2022045996A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/13434 2020-08-26
TR2020/13434A TR202013434A2 (tr) 2020-08-26 2020-08-26 Osteoartrit tedavisinde hyaluronikasit- kollagenle enkapsülenen mezenkimal kök hücre-trombositten zengin plazma ve kondrosit içeren ürün-yöntem

Publications (1)

Publication Number Publication Date
WO2022045996A1 true WO2022045996A1 (fr) 2022-03-03

Family

ID=75526195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2020/050782 WO2022045996A1 (fr) 2020-08-26 2020-08-28 Procédé de production contenant des cellules souches mésenchymateuses, du plasma riche en plaquettes et des chondrocytes encapsulés avec de l'acide hyaluronique-collagène pour le traitement de l'ostéoarthrite

Country Status (2)

Country Link
TR (1) TR202013434A2 (fr)
WO (1) WO2022045996A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171736A1 (fr) * 2012-05-17 2013-11-21 Cartiheal(2009) Ltd Biomatrices hydrogels et leurs procédés d'utilisation
WO2017168428A1 (fr) * 2016-03-30 2017-10-05 Regentis Biomaterials Ltd. Traitements à base d'un conjugué polymère-protéine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171736A1 (fr) * 2012-05-17 2013-11-21 Cartiheal(2009) Ltd Biomatrices hydrogels et leurs procédés d'utilisation
WO2017168428A1 (fr) * 2016-03-30 2017-10-05 Regentis Biomaterials Ltd. Traitements à base d'un conjugué polymère-protéine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMANN ELISABETH; WOLFF PAUL; BREEL ERNST; VAN GRIENSVEN MARTIJN; BALMAYOR ELIZABETH R.: "Hyaluronic acid facilitates chondrogenesis and matrix deposition of human adipose derived mesenchymal stem cells and human chondrocytes co-cultures", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 52, 25 January 2017 (2017-01-25), AMSTERDAM, NL, pages 130 - 144, XP029968296, ISSN: 1742-7061, DOI: 10.1016/j.actbio.2017.01.064 *
KONTTURI LEENA-STIINA, JÄRVINEN ELINA, MUHONEN VIRPI, COLLIN ESTELLE C., PANDIT ABHAY S., KIVIRANTA ILKKA, YLIPERTTULA MARJO, URTT: "An injectable, in situ forming type II collagen/hyaluronic acid hydrogel vehicle for chondrocyte delivery in cartilage tissue engineering", DRUG DELIVERY AND TRANSLATIONAL RESEARCH, SPRINGER, GERMANY, vol. 4, no. 2, 1 April 2014 (2014-04-01), Germany , pages 149 - 158, XP055911155, ISSN: 2190-393X, DOI: 10.1007/s13346-013-0188-1 *

Also Published As

Publication number Publication date
TR202013434A2 (tr) 2020-10-21

Similar Documents

Publication Publication Date Title
Moshaverinia et al. Dental mesenchymal stem cells encapsulated in an alginate hydrogel co-delivery microencapsulation system for cartilage regeneration
Kuhbier et al. Isolation, characterization, differentiation, and application of adipose-derived stem cells
US8192987B2 (en) Human dental follicle stem cells and methods for obtaining
US20140234276A1 (en) Means and methods for liver regeneration
US20080187518A1 (en) Production of Osteoclasts from Adipose Tissues
KR20160034244A (ko) 단리된 추간판 세포, 사용 방법, 및 포유류 조직으로부터 이를 제조하는 방법
WO2014148592A1 (fr) Procédé de préparation de chondrocytes
Wu et al. Hyaluronan microenvironment enhances cartilage regeneration of human adipose-derived stem cells in a chondral defect model
Muttigi et al. Matrilin‐3 codelivery with adipose‐derived mesenchymal stem cells promotes articular cartilage regeneration in a rat osteochondral defect model
AU2013206755B2 (en) Activating adipose-derived stem cells for transplantation
BRPI0616708A2 (pt) métodos para diferenciar células-tronco e uso das mesmas no tratamento de condições dentárias
KR20210040908A (ko) 인간 유도 만능 줄기세포로부터 연골세포의 펠렛을 제조하는 방법 및 이의 용도
Liang et al. Progress in the treatment of osteoarthritis with umbilical cord stem cells
ES2360153B9 (es) Composicion de implante para regeneracion de tejido neural, metodo deobtencion y usos de la misma
Zheng et al. Co-culture pellet of human Wharton’s jelly mesenchymal stem cells and rat costal chondrocytes as a candidate for articular cartilage regeneration: in vitro and in vivo study
US8709401B2 (en) Primed stem cells and uses thereof to treat inflammatory conditions in joints
Huang et al. Codelivery of synovium-derived mesenchymal stem cells and TGF-β by a hybrid scaffold for cartilage regeneration
KR102223043B1 (ko) 활액막 유래 중간엽 줄기세포 및 그의 용도
US20120087983A1 (en) Orthopedic application of encapsulated stem cells
WO2022045996A1 (fr) Procédé de production contenant des cellules souches mésenchymateuses, du plasma riche en plaquettes et des chondrocytes encapsulés avec de l'acide hyaluronique-collagène pour le traitement de l'ostéoarthrite
Xu et al. Co-culture of annulus fibrosus cells and bone marrow mesenchymal stem cells
Chen et al. Synergistic effects of Indian hedgehog and sonic hedgehog on chondrogenesis during cartilage repair
Bochkov et al. Methodological guidelines for genetic safety testing of cell transplants
Gugjoo Therapeutic Applications of Mesenchymal Stem Cells in Veterinary Medicine
Vigano Mesenchymal Stem Cells for the treatment of osteoarthritis and tendinopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20951754

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20951754

Country of ref document: EP

Kind code of ref document: A1